Question to the Department for Business, Energy and Industrial Strategy:

To ask the Secretary of State for Business, Energy and Industrial Strategy, whether the forthcoming independent review of the landscape of UK research organisations referenced in the UK Innovation Strategy will consider the proportion of institutions’ work that includes the use of advanced cultures of human cells and tissues, artificial intelligence and organ-on-a-chip technology and other new approach methodologies (NAMs).

As announced in the Innovation Strategy, Nobel Laureate Professor Sir Paul Nurse is leading an independent Review of the Research, Development, and Innovation Organisational Landscape. The Review will draw on the UK’s strengths and experiences and international best practice to enhance the UK research, development, and innovation (RDI) landscape for the future.

The Review focuses on those organisations performing research activity and whether the current institutional mix is calibrated to deliver the highest quality research. It will support the UK RDI landscape to remain world-class and competitive in an increasingly globalised and contested environment.

The Terms of Reference for the Review were published on 1 October 2021. A final report is expected to be published in Spring 2022.